OBJECTIVE: The aim of this study was to evaluate the prognostic impact of p53 alteration in human uterine endometrial adenocarcinoma. METHODS: One hundred and thirty-one patients with primary endometrial adenocarcinoma were included in the study. The p53 mutation and/or protein expression were evaluated by polymerase chain reaction-single-strand conformational polymorphism and by immunohistochemical analysis, respectively. Clinical and pathological parameters were obtained from medical records. Survival data were estimated using Kaplan-Meier estimates and compared with the log-rank test where indicated. Multivariate analysis was performed using the Cox regression method. RESULTS: Thirty nine cases (29.8%) containing p53 alterations had a lower disease specific-survival rate and disease-free survival rate than those without p53 alterations. Statistically significant correlations were seen between p53 alteration and non-endometrioid histology type, high grade tumors, and the absence of progesterone receptor. Multivariate analyses showed that both p53 alteration and FIGO stage at diagnosis were adverse prognostic factors. The group of women with p53 alteration had an 11.0-fold increased risk of disease specific death (95% confidence interval: 1.008-120.765) compared to women whose tumors lacked p53 alteration. CONCLUSION: p53 alteration defines a subset of endometrial adenocarcinoma with highly aggressive behavior and predicts lower survival in patients with endometrial adenocarcinoma.
OBJECTIVE: The aim of this study was to evaluate the prognostic impact of p53 alteration in human uterine endometrial adenocarcinoma. METHODS: One hundred and thirty-one patients with primary endometrial adenocarcinoma were included in the study. The p53 mutation and/or protein expression were evaluated by polymerase chain reaction-single-strand conformational polymorphism and by immunohistochemical analysis, respectively. Clinical and pathological parameters were obtained from medical records. Survival data were estimated using Kaplan-Meier estimates and compared with the log-rank test where indicated. Multivariate analysis was performed using the Cox regression method. RESULTS: Thirty nine cases (29.8%) containing p53 alterations had a lower disease specific-survival rate and disease-free survival rate than those without p53 alterations. Statistically significant correlations were seen between p53 alteration and non-endometrioid histology type, high grade tumors, and the absence of progesterone receptor. Multivariate analyses showed that both p53 alteration and FIGO stage at diagnosis were adverse prognostic factors. The group of women with p53 alteration had an 11.0-fold increased risk of disease specific death (95% confidence interval: 1.008-120.765) compared to women whose tumors lacked p53 alteration. CONCLUSION:p53 alteration defines a subset of endometrial adenocarcinoma with highly aggressive behavior and predicts lower survival in patients with endometrial adenocarcinoma.
Authors: Oluwole Fadare; Katja Gwin; Mohamed M Desouki; Marta A Crispens; Howard W Jones; Dineo Khabele; Sharon X Liang; Wenxin Zheng; Khaled Mohammed; Jonathan L Hecht; Vinita Parkash Journal: Mod Pathol Date: 2013-03-22 Impact factor: 7.842
Authors: Sylwia M Łapińska-Szumczyk; Anna M Supernat; Hanna I Majewska; Jacek Gulczyński; Wojciech Biernat; Dariusz Wydra; Anna J Żaczek Journal: Int J Clin Exp Med Date: 2015-11-15
Authors: Anne M Schultheis; Luciano G Martelotto; Maria R De Filippo; Salvatore Piscuglio; Charlotte K Y Ng; Yaser R Hussein; Jorge S Reis-Filho; Robert A Soslow; Britta Weigelt Journal: Int J Gynecol Pathol Date: 2016-07 Impact factor: 2.762